Not a member? Sign Up

Reasons for Joining

    Address your challenges through knowledge sharing with peers from our global network of specialists.

    Benchmark your business initiatives with the who's who in the field.

    Hear from industry pioneers how to maximize ROI in today's challenging economy.

    And best of all It's FREE!
Sign in using your existing
Pharma IQ account
Username or Email:

Sign Up  |  Already a member? Sign In  |  Visit IQPC.com  
Pharma IQ


Pharmacovigilance: 5 Predictions for 2013

Contributor:  Deepa Arora
Posted:  02/05/2013  12:00:00 AM EST  |  0

Rate this Column: (4.6 Stars | 38 Votes)
Tags:   Pharmacovigilance predictions for 2013 | New EU Regulations | Public Participation in Pharmacovigilance | Spending on Pharmacovigilance | Systematic learning | Pharmacovigilance 2020

Wondering what 2013 might look like for Pharmacovigilance,  here are some predictions that can help you with better planning…

Post Authorization Safety studies
Over the last few years, spontaneous passive reporting has been the cornerstone of pharmacovigilance, however,  the role of post-authorization safety studies and stimulated reporting is predicted to increase tremendously. Although spontaneous reporting will continue to play a central role, planned post-marketing studies will be helpful in the early identification of new adverse reactions.
 
New EU Regulations
 
Since 2009, EU authorities have been working hard to put together new EU regulations. Although, new EU regulations came into effect in 2012, several aspects of these will be implemented in 2013, thus keeping pharma companies and their outsourced partners extremely busy.
 
Some of these include a new template for PSURs, a new EURD list, a new format for RMPs and signal detection in EudraVigilance. Further  modules of safety communication, public participation in Pharmacovigilance, international cooperation and risk minimization measures are planned to be released in various quarters of 2013.
 
Public Participation in Pharmacovigilance
 
Reporting by patients and consumers will increase consistently and they are expected to play a greater role in the early identification of new adverse reactions.
 
The growing importance of the public- regulator partnership is also underlined by the new EU regulation which requires that companies also submit consumer reports (not medically confirmed) on an expedited basis.
 
EMA is also planning to release module XI- Public Participation in Pharmacovigilance in the second quarter of 2013. Emphasis will be on 3-way communication, where companies will also be expected to implement risk minimization programs that include direct safety communications to consumers along with communication to health care practitioners responsible for prescribing, dispensing and administering.
 
Spending on Pharmacovigilance
 
Just like previous years, the scope of pharmacovigilance and pharmacovigilance activities will continue  to increase and so will  the spending on pharmacovigilance. Spending on pharmacovigilance will increase both in regulated as well as semi-regulated markets, however, the trends will be different.
 
In regulated markets, the focus will be on risk management planning including risk minimization and additional pharmacovigilance activities, whereas semi-regulated markets will continue to focus on improving the compliance with routine pharmacovigilance activities.
 
Systematic learning of Pharmacovigilance
 
With the implementation of the EU2P program and several other certificate courses, learning of pharmacovigilance is expected to be more streamlined. This is expected to bring  efficiency in pharmacovigilance activities, otherwise directed at regulatory compliance. Systematic learning of pharmacovigilance is the requirement of the day, and I am hoping to see some more courses well-equipped to provide systematic training in Pharmacovigilance as a result.
 
We will continue to monitor the developments in pharmacovigilance to report to you the latest activities and trends in pharmacovigilance. Keep Reading…

INTERESTED IN LEARNING MORE ABOUT THIS TOPIC?
  4th Annual Pharmacovigilance Asia 2013
Learn practical tips to implement risk management, audit, inspection and adverse drug reaction management strategies whilst complying to regulatory requirements

Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.



Deepa Arora Contributor:   Deepa Arora


* = required.

Not a member yet? Sign up
User Name:
Password:
You Should Check Out:


Be the first to leave a comment
Sign in or Sign up to post a comment

Advertisement

Events of Interest
Download Brochure

Please complete the information below to complete your download.

Please note: That all fields marked with an asterisk (*) are required.

First Name *
Last Name *
Job Title *
Company Name *
Email Address *
Telephone *
Country *
Where did you hear about us? *

I would like to receive information about sponsorship and exhibition opportunities

Yes, sign me up for the FREE Pharma IQ e-newsletter, including information on FREE Podcasts, Webinars, event discounts and online learning opportunities.

Advertisement

Recent Activity